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Abstract 
Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastroin-
testinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or 
advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase 
inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and 
clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the manage-
ment of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines.
Case presentation: Here we report two patients affected by metastatic GIST, treated with radiotherapy and radiosur-
gery in combination with TKIs, achieving an unexpected objective response in the first case and a significant clinical 
benefit associated with a local tumor control of several months in the second case.
Conclusions: These and other successful experiences that are progressively accumulating, open up new scenarios of 
use of radiation therapy in various settings of treatment. GIST is not universally radioresistant and radiotherapy, espe-
cially if combined with molecularly targeted therapy, can improve the outcomes for patients diagnosed with GIST.
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Background
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal tumors of the gastrointestinal 
tract. Previously classified as leiomyomas, leiomyosar-
comas, leiomyoblastomas or schwannomas, they are 
now recognized as a distinct entity, arising from the 
interstitial cells of Cajal or their precursors, specialized 
pacemaker playing a critical role in the coordination of 
normal motility within the gastrointestinal tract.
GIST molecular pathophysiology is a mutation-driven 
process, in most cases (85–90%) a gain-of-function KIT 
gene mutations, which lead to constitutive activation of 
KIT kinase activity and to uncontrolled cell prolifera-
tion. A notably smaller proportion (5–8%) is associated 
with analogous mutations in platelet-derived growth fac-
tor receptor α (PDGFRα) and <10% contain no identi-
fied receptor tyrosine-kinase mutations, referred as KIT/
PDGFRA wild-type GISTs [1–4].
The advent of the tyrosine kinase inhibitors has dra-
matically revolutionized the therapeutic approach to gas-
trointestinal stromal tumor and improved the outcome of 
these patients, becoming the standard systemic therapies 
for locally advanced/metastatic GIST [5, 6].
Most patients obtain good, durable responses to treat-
ment; nevertheless, almost the great majority of patients 
in a metastatic setting develop resistance, leading to 
failure of tyrosine-kinase inhibitors and bringing the 
clinicians to consider an increasingly wide spectrum of 
loco-regional treatment options.
The decisions are based on the specific clinical his-
tory of each patient and have the aim of maximizing the 
Open Access
Clinical Sarcoma Research
*Correspondence:  maria.pantaleo@unibo.it 
1 Department of Specialized, Experimental, and Diagnostic Medicine, S. 
Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Full list of author information is available at the end of the article
Page 2 of 6Gatto et al. Clin Sarcoma Res  (2017) 7:1 
duration of each therapeutic method and, ultimately, the 
overall sequential treatment strategy.
Historically GIST has been considered radiation-resist-
ant, and radiotherapy is recommended only for palliative 
purpose of bone metastases in current treatment guide-
lines [7].
However, some experiences accumulated in recent 
times, including ours, suggest that GIST metastases are 
moderately radiosensitive, and frequently stabilize for 
several months with radiotherapy.
Radiotherapy appears to be a well-tolerated treatment 
that should be considered in the management of meta-
static GIST not only with palliative purposes but, in our 
opinion, even in other settings of treatment.
In this article, we report the strategy of integration 
between radiotherapy and medical treatment, focusing 
on new potential scenarios not explored yet, that may 
enlarge the treatment opportunities for these patients.
Cases presentation
Case 1
In October 2008 a 62 years old male underwent urgency 
total gastrectomy due to a massive hematemesis. Histo-
logical examination revealed a CD 117 positive, DOG 1 
positive gastric GIST with high risk of recurrence accord-
ing to Miettinen classification (6  cm of diameter, 15 
mitoses per 50 high power field). No tumor rupture was 
observed.
In January 2010, a CT scan documented the appear-
ance of multiple liver metastases, thus the patient was 
enrolled in CAMN107G2301 trial and a first line therapy 
with imatinib mesylate at a daily dose of 400  mg was 
started. The treatment was pursued regularly, with good 
tolerance and stability of disease until July 2011, when 
a mild increase in size of hepatic lesions led to stop the 
trial and an imatinib dose escalation to 800 mg/day was 
started.
In May 2012 a new solid paracaval lesion with throm-
bosis of the inferior vena cava was identified (diameter 
27 × 45 mm), and therapy was switched to a second line 
treatment with oral sunitinib at the dose of 37.5 mg/day.
A CT scan after 5  months of sunitinib treatment 
showed progression in the size of the paracaval lesion 
(diameter 130 × 110 mm) with compression of the vena 
cava and coeliac trunk, therefore we discontinued suni-
tinib and prescribed regorafenib 160 mg/day (21 days on, 
7 days off). The mass became quickly symptomatic with 
local pain and hiccup. A surgical consultation excluded 
reintervention because of the site of disease, insepara-
ble from the great vessels, and because of the sequelae of 
previous surgery.
In view of the symptoms development, of the rapid 
increase in size of the mass (about 8 cm in few months) 
and in absence of surgical options, in November 2012 
we administered external radiotherapy combined with 
regorafenib at a dose of 160 mg/day.
A dose of 35 Gray was administered in 14 sessions, 
with good subjective tolerance by the patient and with-
out complications, obtaining an objective response, with 
decrease in size of the paracaval mass from 130 to 80 mm 
and clinical benefit on pain (Fig. 1).
Despite a regorafenib dose reduction for toxicity 
(120 mg/day—21 days on, 7 days off schedule) the patient 
has maintained a stable disease, both in the liver and in 
the radio-treated mass, for over three years, until now.
Case 2
In January 2012, a 44 years-old male diagnosed with gas-
tric GIST with multiple liver metastases and previously 
treated with imatinib and sunitinib was referred to our 
institution.
Clinically the patient complained a number of symp-
toms related to compression of the tumor, mainly nausea, 
vomiting and abdominal pain.
Because of the clinical picture, the young age and the 
lack, at that time, of approved third-line therapies, we 
decided for a debulking surgery.
In March 2012 a partial gastrectomy and right hepa-
tectomy were performed, histology confirming the diag-
nosis of GIST with a high mitotic index (mitoses 30/50 
high power field). The surgical approach was no radical, 
with residual hepatic disease, thus, after post-operative 
recovery, a medical treatment with imatinib 400 mg/day 
was resumed, subsequently increased to 800 mg/day for 
increase in size of liver metastases.
In October 2013 a CT scan documented the appear-
ance of a new lesion below the diaphragm in the right 
pararenal (diameter 34  mm) associated with significant 
pain, poorly responsive to opioids.
Considering the exclusively focal progression of dis-
ease and the symptoms development we decided for 
local radiosurgery: a cyberknife treatment was performed 
(at first 4500  cGy delivered in 5 sessions; after 60  days 
repeated a second dose of 4000 cGy fractionated in 4 ses-
sions), well-tolerated, burdened only by nausea which 
required a discontinuation of imatinib during sessions. 
Radiological assessment after cyberknife showed disease 
stabilization without shrinkage of tumor size, but with a 
decrease in hypervascularity of the mass, and the patient 
referred an early improvement in pain (Fig.  2). Few 
months later the patient developed a critical left supra-
clavicular mass (diameter 46  ×  37  mm), progressively 
increasing and displacing the trachea, causing worsen-
ing pain, hacking cough and dysphagia. In this phase we 
decided for a combination strategy, integrating medical 
treatment with sunitinib rechallange with a cyberknife 
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treatment of the supraclavicular mass (total dosage 
of 32 Gy in 5 sessions). Also in this case, in addition to 
a dimensional stabilization of the lesion, the patient 
obtained a substantial clinical benefit.
Unfortunately, in the following months, our patient 
exhibited a rapid disease progression, whilst maintain-
ing a dimensional stability of the radiosurgical-treated 
masses (for about 5 months) and a prolonged symptoms 
control.
Discussion
Although the role of radiation therapy is well established 
for the treatment of soft tissue sarcomas, GIST has been 
historically considered radioresistant [8, 9], and the use 
of this method has been discouraged mainly because of 
the elective abdominal pattern of spread, which require 
too large fields of irradiation, often resulting in unaccep-
table bowel toxicity.
Based on these considerations, currently the use of 
radiation therapy in GIST is rarely considered and is 
recommended only for the palliative treatment of bone 
metastases [7].
However, to date some publications suggest the efficacy 
of radiation therapy in the management of GIST [10–12].
Herein we report two very peculiar cases suggesting a 
possible successful use of radiotherapy as an integrated 
approach in GIST management, to obtain a long lasting 
disease stabilization, and, in selected cases, even objec-
tive responses.
In the first case we combined radiotherapy with 
regorafenib for the treatment of a voluminous, progres-
sively increasing and symptomatic paracaval lesion, 
Fig. 1 a CT scan documenting a voluminous GIST metastasis compressing the vena cava (diameter 130 × 110 mm). b CT scan performed 
4 months after radiotherapy showing significant tumor shrinkage
Fig. 2 a CT scan documenting right pararenal hypervascular metastatsis (diameter 34 mm). b CT scan performed after cyberknife. The lesion, 
substantially stable in size, became completely hypodense
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obtaining not only a symptoms control but also a signifi-
cant tumor shrinkage for three years.
The second case, instead, is the first published experi-
ence, to our knowledge, of cyberknife treatment in GIST. 
Cyberknife is a device that combines a robotic arm with 
a linear accelerator, has been developed for stereotactic 
radiotherapy and may provide an adequate dose to the 
tumor while decreasing the dose to the surrounding nor-
mal tissue. Cyberknife was administered in both a para-
renal and a supraclavicular mass, at different times, and 
resulted in a well-tolerated treatment which provided 
local control of the masses and rapid improvement of the 
symptoms.
Currently the standard of care for resectable GIST 
is surgery, followed by adjuvant imatinib for high risk 
recurrence. Inoperable or metastatic tumors are treated 
primarily with imatinib, which should be pursued indefi-
nitely until the development of progression that occurs, 
generally, after a median time of 24 months [13].
For patients who progress to imatinib, sunitinib is an 
effective treatment option and currently represent the 
only proven second-line therapy for advanced GISTs [14]. 
However, due to the development of resistance to both of 
these two drugs in the majority of patients, the need for 
third-line therapy arose. Based on the phase III placebo-
controlled GRID trial, regorafenib, an oral multi-targeted 
inhibitor with activity against multiple kinases including 
KIT, RET, RAF1, BRAF, PDGFR, FGFR and angiogenesis 
(VEGFR), has shown an increase of median PFS (4–8 vs 
0–9 months in regorafenib group, p < 0.0001)and is now 
established as the third-line therapy of metastatic GISTs 
[15].
In recent years the development of three lines of ther-
apy has improved a lot the prognosis and survival of 
patients with GIST, making more and more evident the 
need not only of further lines of therapy, but, above all, 
the necessity of multidisciplinary approaches in order to 
maximize the clinical benefit and the duration of treat-
ment with each single agent. In this context we invite 
to consider much more the role of radiation therapy in 
GIST, which could prove to be invaluable, as it has been 
for the radiofrequency ablation of liver metastases, now 
definitively imposed as a successful option in providing 
effective local tumor control, especially if combined with 
TKIs therapy [16, 17].
There are several scenarios in which radiation therapy 
may provide a potential benefit:
I.  radiotherapy of metastases for palliation of local 
symptoms with low toxicities, a possibility already 
widely explored
II.  radiotherapy of focally progressing lesions, with the 
aim of overcoming emergent resistant clones, not 
only with a palliative intent but also cytoreductive, in 
combination with systemic therapy which continue 
acting on the sensitive clones
III. in the peri-operative setting, combined with 
imatinib, especially for GIST at high risk of local 
recurrence, where surgery is often demolitive, such 
as rectal and esophageal GIST
IV. definitive radiotherapy alternative to surgery in 
localized GIST in elderly patients with comorbidities 
or in case of unresectable tumors
In the largest published series, Joensuu et al. presented 
a phase II prospective study of 25 patients affected by 
liver, soft-tissue, intra-abdominal and bone GIST metas-
tases, treated with external beam radiotherapy, at a 
cumulative dose of approximately 40  Gy, whilst main-
taining systemic therapy during irradiation (11 patients 
continued to receive imatinib, 4 sunitinib, 2 nilotinib, 
1 regorafenib and 1 a combination of sorafenib and 
everolimus). Two patients achieved partial remission, 20 
patients had a durable stabilization of the target lesion, 
with a median duration of stabilization of 16 months, and 
only 3 progressed (9).
Obviously it is difficult to determine if the systemic 
therapy is a confounding factor in assessing the response 
to a local treatment and if it can increase sensitivity to 
radiotherapy. Realistically the efficacy achieved could 
result rather from the combined effects of radiotherapy 
and tyrosine kinase inhibitors, and might be less with 
radiation alone.
Some studies suggest that imatinib can increase the 
radiosensitivity in cell lines, specifically human glioma 
and anaplastic thyroid cancer cell lines. In particular, 
imatinib can reduce the levels of cellular RAD51, an 
essential component of the homologous DNA repair 
pathway implicated as a determinant of cellular radiosen-
sitivity, leading to increased radiosensitivity in vitro and 
in  vivo without undue toxicity toward normal cells and 
tissues [18, 19].
Ciresa et al. described a successful use of neo-adjuvant 
radiotherapy in a case of rectal GIST extending to the 
anal canal, who received imatinib 400  mg/day and con-
comitant radiotherapy (total dose 50.4 Gy in fractions of 
1.8 Gy daily) obtaining a partial clinical response 3 weeks 
after the end of combination treatment. The patient then 
underwent a sphincter-saving surgical procedure, with a 
complete pathological response at the histological exami-
nation [20].
Although there are no prospective data that produce 
this evidence, radiotherapy may be considered, associated 
with TKI and preferably in the context of clinical stud-
ies, in the treatment of GIST and in particular of those in 
the rectal, esophageal and duodenal site, to evaluate the 
Page 5 of 6Gatto et al. Clin Sarcoma Res  (2017) 7:1 
effectiveness of this approach in both the down-staging 
and the prevention of local recurrence as well as for the 
epithelial counterpart, even though it is well known the 
histology is completely different.
Regarding the cyberknife, it is an image-guided framel-
ess robotic technology for whole-body radiosurgery, used 
for classic single-fraction radiosurgery and for hypofrac-
tionated treatments, which treat tumors with supreme 
accuracy, essentially “painting” the mass with radiation 
and sparing surrounding healthy tissue.
Unlike some radiosurgery systems, which can only treat 
primary or secondary brain neoplasms, the cyberknife 
may be applicated to extracranial use and has been tested 
in a broad range of tumors, including prostate, lung, 
spine, liver, pancreas, and kidney. However, to our knowl-
edge, no experience has so far been published regarding 
the application of the cyberknife in GIST.
This radiosurgery strategy has emerged as an additional 
tool in oncology armamentarium, extremely attractive for 
the high tumor control, the low toxicity and the repeat-
ability of the treatments for recurrent metastases [21, 22].
Optimal management of patients diagnosed with GIST 
is multidisciplinary, should be performed only at special-
ized oncological center, and requires strong cooperation 
among different expertises, including oncology, surgery, 
ultrasound, radiology, radiotherapy, radiosurgery and 
interventional radiology.
It is not excluded that in the very near future, not 
only radiation but also other approaches such as arterial 
embolization, cyber-knife and HIFU ablation (high inten-
sity focused ultrasound) can carve out a role in the treat-
ment of this tumor, increasingly articulate and complex.
Conclusions
To date, the evidence regarding the use of radiation ther-
apy in GIST is limited to small case series, therefore, the 
impression emerging from these experiences is that this 
approach is effective not only in a strictly palliative field, 
but may also provide objective responses and long-term 
disease control in selected patients, without any signifi-
cant toxicity or impact on quality of life.
We decided to report these two cases because, in our 
view, are very interesting in several aspects: the unex-
pected significant objective response obtained with the 
combination of regorafenib and radiotherapy in the first 
case, and the experience with the technique of cyberknife 
in the second case, which we hope could find an increas-
ingly wide range of use in the immediate future.
We can certainly conclude that radiation therapy, 
unjustifiably underutilized until now, should be consid-
ered a viable option in the treatment of locally advanced\
metastatic GISTs. Nevertheless further studies are 
needed to standardize its correct role in the different 
settings of treatment, but also the effective dosage and 
the irradiation techniques.
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